Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/25/2022 | $6.00 | Buy | Maxim Group |
Maxim Group initiated coverage of NexGel with a rating of Buy and set a new price target of $6.00
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
4 - NEXGEL, INC. (0001468929) (Issuer)
LANGHORNE, Pa., Nov. 21, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, will present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10 and 11, 2024. iAccess Alpha Virtual Conference Details:Date: December 10-11, 2024Presentation Day and Time: Tuesday, December 10th at 10:30 a.m. ETWebcast: https://www.webcaster4.com/Webcast/Page/3074/51540 To schedule a one-on-one investor meeting with Mr. Levy, please contact
Quarterly revenue growth driven by a sequential increase of 99% in branded consumer products and 103% in contract manufacturing Gross profit margin for the quarter was 43.6% compared to 28.2% in Q3 of 2023 and 28.5% in Q2 of 2024 LANGHORNE, Pa., Nov. 13, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced record third quarter revenue of $2.94 million, an increase of 141% year-over-year and 104% sequentially. Third Quarter 2024 Financial Highlights: Net Revenue was $2.94 million, compared to $1.22 million in Q3 2023 and $1.44
LANGHORNE, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ:NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced it has entered into definitive agreements for the issuance and sale of an aggregate of 727,272 of its shares of common stock and the issuance of warrants to purchase up to an aggregate of 363,636 shares of common stock for a combined offering purchase price of $2.75 per share of common stock in a registered direct offering. The warrants will have an exercise price of $4.25 per share and be exercisable immediatel
LANGHORNE, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Kip Crecca to its Scientific Advisory Board. "We are thrilled to appoint Kip to our Scientific Advisory Board. He adds to our team a wealth of knowledge and experience as a top medical device sales professional," said Adam Levy, NEXGEL's CEO. "Mr. Crecca will be invaluable to the Company as we advance our medical device and healthcare programs. He is an important addition to our group of e
LANGHORNE, Pa., Jan. 17, 2023 /PRNewswire/ -- NEXGEL, Inc. (NASDAQ:NXGL, NXGLW))), ("NEXGEL" or the "Company"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced today the appointment of Scott Henry, CFA as a new independent director to the Company's Board of Directors (the "Board"), effective immediately. Mr. Henry will also serve as a member of the Board's Audit Committee. "Scott brings a wealth of financial and operational experience to NEXGEL, making him an ideal addition to our Board and Audit Committee," said Adam Levy, Chief Executive Officer of NEXGEL. "Additionally, his vast network within the investment comm
LANGHORNE, Pa., Sept. 29, 2022 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ:NXGL, NXGLW))), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced today that the Company has appointed Dr. Neil Chesen and Dr. Leonard Nelson to its Scientific Advisory Board. Dr. Nelson serves as Co-Director of the pediatric ophthalmology department and Director of the Strabismus Center at Wills Eye Hospital. He is an associate professor of ophthalmology and pediatrics at Thomas Jefferson University's Sidney Kimmel Medical College and staff member at Thomas Jefferson University Hospital, Lankenau Medical Center and
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the third quarter 2024, after the market close on November 13, 2024. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET on the same day. Third Quarter 2024 Financial Results Conference CallDate: November 13, 2024Time: 4:30 P.M. ETLive Call: 1-800-225-9448 (U.S. Toll Free) or 1-203-518-9708
LANGHORNE, Pa., Oct. 10, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced preliminary, unaudited expected record revenue for the third quarter 2024 of approximately $2.85 million, an increase of approximately 133% year-over-year and approximately 98% quarter-over-quarter, respectively, as well as an increase of approximately 30% over the Company's previously issued July third quarter revenue guidance of $2.20 million. "We are pleased to announce yet another record revenue quarter,
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced it will report its financial results for the second quarter 2024, after the market closes on August 14, 2024. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET on the same day. Second Quarter 2024 Financial Results Conference CallDate: August 14, 2024Time: 4:30 P.M. ETLive Call: + 1-8
10-Q - NEXGEL, INC. (0001468929) (Filer)
424B5 - NEXGEL, INC. (0001468929) (Filer)
8-K - NEXGEL, INC. (0001468929) (Filer)
The 30-patient study is designed to measure the efficacy of applying NEXGEL's hydrogel during laser hair removal in eliminating harmful particles or plume during treatmentsSeveral states have already either instituted or are considering surgical plume protection mandates as a requirement to contain the toxic byproduct of laser proceduresLANGHORNE, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ:NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, and Innovative Optics US dba Vanalay, a leading supplier of safety products and personal prote
With U.S. stock futures trading higher this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Helen of Troy Limited (NASDAQ:HELE) to report quarterly earnings at $1.59 per share on revenue of $445.86 million before the opening bell, according to data from Benzinga Pro. Helen of Troy shares gained 0.3% to $89.30 in the after-hours trading session. NEXGEL, Inc. (NASDAQ:NXGL) issued preliminary revenue guidance above estimates. The company said it sees third-quarter revenue of $2.2 million versus estimates of $2.091 million. It expects fourth-quarter revenue of $2.6 million versus expectations of $2.467 million. NexGel shares ju
Adam Levy, CEO of NEXGEL, commented, "We are pleased to deliver record revenue for the second quarter of 2024 in spite of lower-than-normal revenues at CG Converting and Packaging due to our move into our newly expanded facility. We are also pleased to provide an outlook for our expected results for the second half of this year that has exceeded our expectations for both contract manufacturing and consumer products. The growth in contract manufacturing is primarily due to new customer relationships with large global corporations. Additionally, many of our brands are also experiencing significant growth. Silly George is leading the way with strong consumer demand for our new Pop-On Lash produ